Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 387.20% | 432.03% | 282.17% | 135.59% | 114.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 387.20% | 432.03% | 282.17% | 135.59% | 114.78% |
| Cost of Revenue | 25.01% | 23.86% | 26.73% | 26.58% | 32.72% |
| Gross Profit | 49.64% | 36.97% | 8.93% | -12.54% | -23.04% |
| SG&A Expenses | 1.64% | 1.06% | 3.39% | 5.82% | 16.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.30% | 18.37% | 20.86% | 21.19% | 28.40% |
| Operating Income | 35.25% | 26.82% | 5.51% | -10.63% | -21.18% |
| Income Before Tax | 13.92% | 11.24% | -12.08% | -18.14% | -19.46% |
| Income Tax Expenses | 1,275.00% | 175.00% | -79.17% | -79.17% | -116.67% |
| Earnings from Continuing Operations | 13.89% | 11.24% | -12.07% | -18.12% | -19.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.89% | 11.24% | -12.07% | -18.12% | -19.44% |
| EBIT | 35.25% | 26.82% | 5.51% | -10.63% | -21.18% |
| EBITDA | 35.35% | 26.90% | 5.51% | -10.71% | -21.31% |
| EPS Basic | 21.00% | 14.41% | -12.12% | -22.07% | -26.36% |
| Normalized Basic EPS | 17.31% | 10.34% | -7.04% | -16.77% | -20.69% |
| EPS Diluted | 21.00% | 14.41% | -12.03% | -21.96% | -26.24% |
| Normalized Diluted EPS | 17.31% | 10.34% | -7.04% | -16.77% | -20.69% |
| Average Basic Shares Outstanding | 10.12% | 5.37% | 0.06% | -3.62% | -5.61% |
| Average Diluted Shares Outstanding | 10.12% | 5.37% | 0.06% | -3.62% | -5.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |